Therapeutics News and Research

RSS

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile.

11 Dec 2012

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy.

11 Dec 2012

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced the presentation of new clinical data with the Company's targeted anticancer compound, IMGN901.

11 Dec 2012

Pfizer joins WIN Consortium to improve personalized cancer care

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc (NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

10 Dec 2012

New study could help develop anti-inflammatory drugs with fewer side effects

10 Dec 2012

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform.

10 Dec 2012

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

The pharmaceutical industry is experiencing a massive paradigm shift as the era of the highly profitable blockbusters comes to a close. In an attempt to remain competitive, companies are under more pressure than ever to push novel compounds through the development pipeline and so it has been largely left to those in formulation and delivery to optimise their product portfolio using winning business strategies and leading technologies.

10 Dec 2012

C5aRA treatment could be effective against periodontitis

Periodontitis, a form of chronic gum disease that affects nearly half of the U.S. adult population, results when the bacterial community in the mouth becomes unbalanced, leading to inflammation and eventually bone loss. In its most severe form, which affects 8.5 percent of U.S. adults, periodontitis can impact systemic health.

9 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Novel antidepressant targets brain receptors responsible for learning and memory

A first-of-its-kind antidepressant drug discovered by a Northwestern University professor and now tested on adults who have failed other antidepressant therapies has been shown to alleviate symptoms within hours, have good safety and produce positive effects that last for about seven days from a single dose.

7 Dec 2012

Ultrasound applied to fingertips can stimulate sensory pathways leading to the brain

A century after the world's first ultrasonic detection device - invented in response to the sinking of the Titanic -Virginia Tech Carilion Research Institute scientists have provided the first neurophysiological evidence for something that researchers have long suspected: ultrasound applied to the periphery, such as the fingertips, can stimulate different sensory pathways leading to the brain.

7 Dec 2012

NCI-funded study to identify metabolic vulnerabilities of particularly aggressive cancers

Eileen White, PhD, associate director for basic science at The Cancer Institute of New Jersey and professor of molecular biology and biochemistry at Rutgers, The State University of New Jersey, and colleagues from Princeton University have been awarded a new five-year, $2.4 million dollar research grant from the National Cancer Institute.

7 Dec 2012

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genomic sequencing has revealed therapeutic drug targets for difficult-to-treat, metastatic triple-negative breast cancer (TNBC), according to an unprecedented study by the Translational Genomic Research Institute (TGen) and US Oncology Research.

7 Dec 2012

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Whole genome sequencing has revealed previously unreported mutations in metastatic triple-negative breast cancer (TNBC), according to a study published by the journal Molecular Cancer Therapeutics.

6 Dec 2012

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.

6 Dec 2012

Study questions value of coated, low-dose aspirin therapy

Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets - blood cells that clump together in the first stages of forming harmful clots - up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.

6 Dec 2012

Moderna Therapeutics closes $40M in financing

Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development.

6 Dec 2012

Inserm prizes for medical research to be awarded on Dec. 3

The 2012 Inserm prizes for medical research will be awarded at a ceremony at the Coll-ge de France on Monday 3 December 2012. This year, the grand prize will be awarded to Philippe Sansonetti in the presence of Marisol Touraine, France's Minister of Social Affairs and Health, Genevi-ve Fioraso, France's Minister of Higher Education and Research, and Professor Andr- Syrota, Chairman and CEO of Inserm.

5 Dec 2012

Arthrobotrys oligospora produces nanoparticles that could kill tumors

Arthrobotrys oligospora doesn't live a charmed life; it survives on a diet of roundworm. But a discovery by a team led by Mingjun Zhang, an associate professor of biomedical engineering at the University of Tennessee, Knoxville, could give the fungus's life more purpose-as a cancer fighter.

5 Dec 2012

Therapeutics News and Research

Janssen announces U.S. prescribing information update for EDURANT tablets

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Pfizer joins WIN Consortium to improve personalized cancer care

New study could help develop anti-inflammatory drugs with fewer side effects

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

DOW Chemical to attend the 4th World Drug Delivery & Formulation Summit

C5aRA treatment could be effective against periodontitis

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Novel antidepressant targets brain receptors responsible for learning and memory

Ultrasound applied to fingertips can stimulate sensory pathways leading to the brain

NCI-funded study to identify metabolic vulnerabilities of particularly aggressive cancers

Genomic sequencing reveals therapeutic drug targets for metastatic triple-negative breast cancer

Genome sequencing reveals previously unreported mutations in metastatic TNBC

Naurex reports positive results from GLYX-13 Phase IIa trial on depression

Study questions value of coated, low-dose aspirin therapy

Moderna Therapeutics closes $40M in financing

Inserm prizes for medical research to be awarded on Dec. 3

Arthrobotrys oligospora produces nanoparticles that could kill tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News